MX2016014256A - Formulaciones y metodos para el suministro vaginal de antiprogestinas. - Google Patents
Formulaciones y metodos para el suministro vaginal de antiprogestinas.Info
- Publication number
- MX2016014256A MX2016014256A MX2016014256A MX2016014256A MX2016014256A MX 2016014256 A MX2016014256 A MX 2016014256A MX 2016014256 A MX2016014256 A MX 2016014256A MX 2016014256 A MX2016014256 A MX 2016014256A MX 2016014256 A MX2016014256 A MX 2016014256A
- Authority
- MX
- Mexico
- Prior art keywords
- vaginal
- methods
- antiprogestines
- formulations
- supply
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 208000034423 Delivery Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000000708 anti-progestin effect Effects 0.000 abstract 1
- 239000003418 antiprogestin Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 abstract 1
- 229940105132 myristate Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 abstract 1
- 230000009677 vaginal delivery Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
El objeto de la presente invención se refiere al campo de suministro vaginal de agentes farmacéuticamente activos. Las formas de realización de la presente invención revelan métodos para tratar una variedad de trastornos relacionados con la progesterona mediante la administración vaginal de una cápsula de pululano y una formulación de relleno que comprende una o varias antiprogestinas dispersas en una mezcla de palmitato de isopropilo o miristato de isopropilo y un polietilenglicol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988766P | 2014-05-05 | 2014-05-05 | |
| PCT/US2015/027122 WO2015171319A1 (en) | 2014-05-05 | 2015-04-22 | Formulations and methods for vaginal delivery of antiprogestins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014256A true MX2016014256A (es) | 2017-02-06 |
| MX384159B MX384159B (es) | 2025-03-14 |
Family
ID=54392846
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014256A MX384159B (es) | 2014-05-05 | 2015-04-22 | Formulaciones y métodos para el suministro vaginal de antiprogestinas. |
| MX2020005921A MX2020005921A (es) | 2014-05-05 | 2016-10-31 | Formulaciones y metodos para el suministro vaginal de antiprogestinas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005921A MX2020005921A (es) | 2014-05-05 | 2016-10-31 | Formulaciones y metodos para el suministro vaginal de antiprogestinas. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10064815B2 (es) |
| EP (1) | EP3139908A4 (es) |
| JP (2) | JP6591447B2 (es) |
| CN (2) | CN106232107B (es) |
| AU (1) | AU2015256473B2 (es) |
| CA (1) | CA2948287A1 (es) |
| IL (1) | IL248621B (es) |
| MX (2) | MX384159B (es) |
| WO (1) | WO2015171319A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11576870B2 (en) * | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
| US10857151B1 (en) | 2020-02-21 | 2020-12-08 | Villya LLC | Treatment of female genital schistosomiasis |
| US20220047506A1 (en) | 2020-08-12 | 2022-02-17 | Villya LLC | Praziquantel Formulations |
| WO2024158694A1 (en) | 2023-01-23 | 2024-08-02 | Villya LLC | Compositions and methods for improving the solubility of erectile dysfunction therapeutics |
| EP4417192A1 (en) * | 2023-02-17 | 2024-08-21 | meliodys medical UG | Medical device, kit, method, and anti-inflammatory substance |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| CA2457526A1 (en) * | 2001-08-29 | 2003-03-13 | Umd, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
| US7417013B2 (en) | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
| EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| CA2682752C (en) * | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| DK2214643T3 (da) * | 2007-11-02 | 2014-05-26 | Acrux Dds Pty Ltd | Transdermalt frigivelsessystem til hormoner og steroider |
| SG183924A1 (en) * | 2010-03-22 | 2012-10-30 | Repros Therapeutics Inc | Compositions and methods for non-toxic delivery of antiprogestins |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| CA2856520C (en) * | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| ES2701400T3 (es) * | 2012-05-31 | 2019-02-22 | Repros Therapeutics Inc | Formulaciones para la administración vaginal de antiprogestinas |
-
2015
- 2015-04-22 AU AU2015256473A patent/AU2015256473B2/en not_active Ceased
- 2015-04-22 JP JP2016566245A patent/JP6591447B2/ja not_active Expired - Fee Related
- 2015-04-22 MX MX2016014256A patent/MX384159B/es unknown
- 2015-04-22 WO PCT/US2015/027122 patent/WO2015171319A1/en not_active Ceased
- 2015-04-22 CA CA2948287A patent/CA2948287A1/en not_active Abandoned
- 2015-04-22 CN CN201580022706.0A patent/CN106232107B/zh not_active Expired - Fee Related
- 2015-04-22 EP EP15789148.2A patent/EP3139908A4/en not_active Withdrawn
- 2015-04-22 US US15/308,804 patent/US10064815B2/en not_active Expired - Fee Related
- 2015-04-22 CN CN202010411810.1A patent/CN111840246A/zh active Pending
-
2016
- 2016-10-30 IL IL248621A patent/IL248621B/en active IP Right Grant
- 2016-10-31 MX MX2020005921A patent/MX2020005921A/es unknown
-
2018
- 2018-07-20 US US16/041,378 patent/US10555900B2/en not_active Expired - Fee Related
-
2019
- 2019-08-19 JP JP2019149824A patent/JP6796693B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 US US16/787,830 patent/US20200222315A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10064815B2 (en) | 2018-09-04 |
| EP3139908A4 (en) | 2018-05-16 |
| AU2015256473B2 (en) | 2018-07-12 |
| JP2017514851A (ja) | 2017-06-08 |
| US20170181965A1 (en) | 2017-06-29 |
| IL248621A0 (en) | 2017-01-31 |
| JP6796693B2 (ja) | 2020-12-09 |
| IL248621B (en) | 2020-09-30 |
| EP3139908A1 (en) | 2017-03-15 |
| US20200222315A1 (en) | 2020-07-16 |
| CN111840246A (zh) | 2020-10-30 |
| MX384159B (es) | 2025-03-14 |
| CN106232107A (zh) | 2016-12-14 |
| US20180325810A1 (en) | 2018-11-15 |
| CA2948287A1 (en) | 2015-11-12 |
| JP6591447B2 (ja) | 2019-10-16 |
| US10555900B2 (en) | 2020-02-11 |
| JP2019194271A (ja) | 2019-11-07 |
| HK1232125A1 (zh) | 2018-01-05 |
| WO2015171319A1 (en) | 2015-11-12 |
| MX2020005921A (es) | 2020-08-20 |
| CN106232107B (zh) | 2020-06-05 |
| AU2015256473A1 (en) | 2016-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| MX2019003467A (es) | Formulaciones y metodos para la administracion vaginal de antiprogestinas. | |
| CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| MX387604B (es) | Formulaciones cannabinoides estables. | |
| PE20151416A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| CL2019000248A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| CL2019000247A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX368735B (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| ECSP15005163A (es) | Composiciones líquidas orales pediátricas que contienen nepadutant | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. |